

## SPG20 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP16276b

## **Specification**

## SPG20 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

**Q8N0X7** 

# SPG20 Antibody (C-term) Blocking Peptide - Additional Information

#### **Gene ID 23111**

#### **Other Names**

Spartin, Spastic paraplegia 20 protein, Trans-activated by hepatitis C virus core protein 1, SPG20, KIAA0610, TAHCCP1

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## SPG20 Antibody (C-term) Blocking Peptide - Protein Information

#### Name SPART (HGNC:18514)

#### **Function**

May be implicated in endosomal trafficking, or microtubule dynamics, or both. Participates in cytokinesis (PubMed:<a href="http://www.uniprot.org/citations/20719964" target=" blank">20719964</a>).

#### **Cellular Location**

Cytoplasm. Midbody. Note=Transiently associated with endosomes (PubMed:19580544). Colocalized with IST1 to the ends of Flemming bodies during cytokinesis (PubMed:20719964)

#### **Tissue Location**

Ubiquitously expressed, with highest levels of expression detected in adipose tissue

# SPG20 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.



• Blocking Peptides

## SPG20 Antibody (C-term) Blocking Peptide - Images

## SPG20 Antibody (C-term) Blocking Peptide - Background

SPG20 is a protein containing a MIT (MicrotubuleInteracting and Trafficking molecule) domain, and is implicated inregulating endosomal trafficking and mitochondria function. Theprotein localizes to mitochondria and partially co-localizes withmicrotubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and theprotein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated withthis gene cause autosomal recessive spastic paraplegia 20 (Troyersyndrome).

# SPG20 Antibody (C-term) Blocking Peptide - References

Hooper, C., et al. BMC Biol. 8, 72 (2010) :Milewska, M., et al. J. Neurochem. 111(4):1022-1030(2009)Tsang, H.T., et al. Hum. Mol. Genet. 18(20):3805-3821(2009)Edwards, T.L., et al. Biochem. J. 423(1):31-39(2009)Eastman, S.W., et al. J. Cell Biol. 184(6):881-894(2009)